ATE162402T1 - Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff - Google Patents

Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff

Info

Publication number
ATE162402T1
ATE162402T1 AT91908727T AT91908727T ATE162402T1 AT E162402 T1 ATE162402 T1 AT E162402T1 AT 91908727 T AT91908727 T AT 91908727T AT 91908727 T AT91908727 T AT 91908727T AT E162402 T1 ATE162402 T1 AT E162402T1
Authority
AT
Austria
Prior art keywords
pct
erythrocytes
vaccine containing
oral vaccine
containing antigens
Prior art date
Application number
AT91908727T
Other languages
English (en)
Inventor
Gerald Toh Pang
Robert Llewellyn Clancy
Original Assignee
Flustat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flustat Pty Ltd filed Critical Flustat Pty Ltd
Application granted granted Critical
Publication of ATE162402T1 publication Critical patent/ATE162402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT91908727T 1990-04-24 1991-04-24 Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff ATE162402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ978390 1990-04-24

Publications (1)

Publication Number Publication Date
ATE162402T1 true ATE162402T1 (de) 1998-02-15

Family

ID=3774614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908727T ATE162402T1 (de) 1990-04-24 1991-04-24 Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff

Country Status (15)

Country Link
US (1) US5643577A (de)
EP (1) EP0528859B1 (de)
JP (1) JPH05506233A (de)
KR (1) KR100186783B1 (de)
AT (1) ATE162402T1 (de)
AU (1) AU646257B2 (de)
BR (1) BR9106374A (de)
CA (1) CA2080477A1 (de)
DE (1) DE69128782T2 (de)
DK (1) DK0528859T3 (de)
ES (1) ES2113882T3 (de)
GR (1) GR3026569T3 (de)
HK (1) HK1004060A1 (de)
SG (1) SG46225A1 (de)
WO (1) WO1991016073A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
GB2294268A (en) 1994-07-07 1996-04-24 Procter & Gamble Bleaching composition for dishwasher use
GB9517269D0 (en) * 1995-08-23 1995-10-25 Cortecs Ltd Vaccines
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
HUP0101233A2 (hu) 1997-11-21 2001-08-28 The Procter & Gamble Co. Termékfelhordó
GB2369094A (en) 2000-11-17 2002-05-22 Procter & Gamble Packaging assembly for sheets of water-soluble sachets
WO2002060416A1 (en) * 2001-02-01 2002-08-08 Gendel Limited Polypeptide delivery system and method for their preparation
US20060083702A1 (en) * 2004-04-02 2006-04-20 Thomas Fondin Hair fiber treating method
EP1858841B1 (de) 2004-12-22 2014-11-26 FUJIFILM Corporation Omega-alkoxyperoxycarbonsäure enthaltende zusammensetzung zur sterilisation
CA2690973A1 (en) * 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
GB0901207D0 (en) 2009-01-26 2009-03-11 Innospec Ltd Chelating agents and methods relating thereto
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011138032A2 (en) 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012059112A1 (en) * 2010-11-01 2012-05-10 Mahmoud Abdel Wahed Rafea Development of medical products based on a new discovered function of red blood cells
CN107115314B (zh) * 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
ES2764105T3 (es) 2011-10-17 2020-06-02 Massachusetts Inst Technology Administración intracelular
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
SG10201801188XA (en) 2013-08-16 2018-03-28 Massachusetts Inst Technology Selective delivery of material to cells
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
EP3129767B1 (de) 2014-03-27 2021-09-01 Academia Sinica Reaktive markierungsverbindungen und ihre verwendungen
DK3149045T3 (da) 2014-05-27 2023-03-06 Academia Sinica Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
EP3191500A4 (de) 2014-09-08 2018-04-11 Academia Sinica Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
RU2739794C2 (ru) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
JP6846345B2 (ja) 2014-11-14 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー 破壊及び場による細胞への化合物及び組成物の送達
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
AU2016289530B2 (en) 2015-07-09 2021-05-06 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
GB2625450A (en) 2022-12-16 2024-06-19 Innospec Performance Chemicals Italia Srl Compositions
GB202409569D0 (en) 2024-07-02 2024-08-14 Innospec Performance Chemicals Italia Srl Compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
FR2355507A1 (fr) * 1976-06-25 1978-01-20 Inst Nat Sante Rech Med Vaccin antiparasitaire par voie orale, son procede de preparation et sa methode d'application chez les mammiferes
SU649435A1 (ru) * 1977-06-24 1979-02-28 Уфимский Научно-Исследовательский Институт Вакции И Сывороток Им. И.И.Мечникова Способ приготовлени эритроцитов
US4403037A (en) * 1980-10-10 1983-09-06 American Hoechst Corporation Erythrocyte preparations and use thereof in hemagglutination tests
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4904468A (en) * 1987-06-08 1990-02-27 Norden Laboratories, Inc. Canine coronavirus vaccine

Also Published As

Publication number Publication date
EP0528859B1 (de) 1998-01-21
EP0528859A4 (en) 1993-08-04
AU646257B2 (en) 1994-02-17
AU7753191A (en) 1991-11-11
DE69128782T2 (de) 1998-09-10
DK0528859T3 (da) 1998-09-14
EP0528859A1 (de) 1993-03-03
WO1991016073A1 (en) 1991-10-31
SG46225A1 (en) 1998-02-20
CA2080477A1 (en) 1991-10-25
ES2113882T3 (es) 1998-05-16
KR100186783B1 (ko) 1999-05-01
DE69128782D1 (de) 1998-02-26
HK1004060A1 (en) 1998-11-13
BR9106374A (pt) 1993-03-30
GR3026569T3 (en) 1998-07-31
US5643577A (en) 1997-07-01
JPH05506233A (ja) 1993-09-16

Similar Documents

Publication Publication Date Title
DE69128782D1 (de) Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DK257485A (da) Farmaceutiske praeparater til oral indgift
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
AR063315A2 (es) Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus
ES2118963T3 (es) Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
EA199800272A1 (ru) Фактор, стимулирующий дендритные клетки
AU2684792A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
CA2098021A1 (en) Composition Used as a Therapeutic Agent Against Chronic Viral Hepatic Diseases
KR850001700A (ko) 단순 헤르페스 바이러스 서브유니트 왁진(Herpes Simplex Virus Subuait Vaccine)의 제조방법
CA2115927A1 (en) Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
DK0666754T3 (da) Syntetisk lungesurfactant med antioxidant-egenskaber
Rhodes Modulation of macrophage Fc receptor expression in vitro by insulin and cyclic nucleotides
CA2078605A1 (en) Chicken anaemia agent vaccine
DK482185A (da) Peptider, deres fremstilling og anvendelse som laegemidler
HK141494A (en) Peptide fragments of HIV
FI885441L (fi) Nya vaccin.
DK178188D0 (da) Antivirusmiddel
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
IT1177147B (it) Composizione farmaceutica per combattere infezioni virali, e procedimento di uso per le infezioni virali
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
ATE18007T1 (de) Hepatitisimpfstoff.
ES2062502T3 (es) Una proteina de factor i pura y un procedimiento para obtener dicha proteina.
ATE234861T1 (de) Influenzaimpfstoff, der als sinergistischer zusatzmittel influenzavirusinnenkörper enthält

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee